The LEADER, SUSTAIN-6, HARMONY and REWIND studies [3–7] found lower rates of cardiovascular events among high-risk individuals with type 2 diabetes treated with the GLP-1 analogues liraglutide, semaglutide, albiglutide and dulaglutide, respectively, vs placebo. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.